404 related articles for article (PubMed ID: 31506282)
1. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.
de Weerdt I; Hofland T; de Boer R; Dobber JA; Dubois J; van Nieuwenhuize D; Mobasher M; de Boer F; Hoogendoorn M; Velders GA; van der Klift M; Remmerswaal EBM; Bemelman FJ; Niemann CU; Kersting S; Levin MD; Eldering E; Tonino SH; Kater AP
Blood Adv; 2019 Sep; 3(17):2642-2652. PubMed ID: 31506282
[TBL] [Abstract][Full Text] [Related]
2. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Eyre TA; Roeker LE; Fox CP; Gohill SH; Walewska R; Walter HS; Forconi F; Broom A; Arumainathan A; Brander DM; Allan JN; Schuster SJ; Hill BT; Lansigan F; Cheson BD; Lamanna N; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Pearson L; Pagel JM; Jacobs R; Mato AR
Br J Haematol; 2020 Mar; 188(6):918-923. PubMed ID: 31682002
[TBL] [Abstract][Full Text] [Related]
4. How I manage CLL with venetoclax-based treatments.
Wierda WG; Tambaro FP
Blood; 2020 Apr; 135(17):1421-1427. PubMed ID: 32076705
[TBL] [Abstract][Full Text] [Related]
5. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Salvaris R; Opat S
Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Anderson MA; Tam C; Lew TE; Juneja S; Juneja M; Westerman D; Wall M; Lade S; Gorelik A; Huang DCS; Seymour JF; Roberts AW
Blood; 2017 Jun; 129(25):3362-3370. PubMed ID: 28473407
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
8. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax for the treatment of chronic lymphocytic leukemia.
Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F
Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Scott LJ
Target Oncol; 2019 Oct; 14(5):493-504. PubMed ID: 31542870
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells.
Teh CE; Peng H; Luo MX; Tan T; Trussart M; Howson LJ; Chua CC; Muttiah C; Brown F; Ritchie ME; Wei AH; Roberts AW; Bryant VL; Anderson MA; Lindeman GJ; Huang DCS; Thijssen R; Gray DHD
Blood Adv; 2023 Jun; 7(12):2733-2745. PubMed ID: 36521105
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia.
Guru Murthy GS; Atallah E
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):346-350. PubMed ID: 37363977
[TBL] [Abstract][Full Text] [Related]
13. Venetoclax: A new wave in hematooncology.
Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R
Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
Crombie J; Davids MS
Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
[TBL] [Abstract][Full Text] [Related]
16. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M; Potluri J; Choi M
Br J Haematol; 2019 Jun; 185(5):961-966. PubMed ID: 30478940
[No Abstract] [Full Text] [Related]
18. Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
.
Brumbaugh Paradis H; Alter D; Llerandi D
Clin J Oncol Nurs; 2017 Oct; 21(5):604-610. PubMed ID: 28945711
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.
Elias EE; Sarapura Martinez VJ; Amondarain M; Colado A; Cordini G; Bezares RF; Fernandez Grecco H; Custidiano MDR; Sánchez Ávalos JC; Garate G; Pavlovsky MA; Borge M; Giordano M; Gamberale R
Cancer Immunol Immunother; 2022 Apr; 71(4):979-987. PubMed ID: 34467417
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
